Firma Kuros Biosciences, Autor bei Presse-Blog

Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference

1. Februar 2024 Firma Kuros BiosciencesForschung und Entwicklungbiomed, bone, cells, clinical, ecm, graft, kuros, magnetos, new, patients, posterolateral, risks, spinal, spine, statements

Kuros Biosciences (“Kuros” or “the Company”), a leader in next generation bone graft technologies, today announced it will present at the CG 2024 Musculoskeletal Conference, to be held in San Francisco on February 12, 2024. At the conference, management will Mehr

Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand

31. Januar 2024 Firma Kuros BiosciencesAllgemeinbone, ecm, flex, Gold, graft, implant, kuros, magnetos, market, maxa, patients, posterolateral, putty, statements, with

MagnetOs™ Granules becomes the third product in the MagnetOs portfolio to receive FDA clearance to market for interbody use Kuros continues expansion of the MagnetOs franchise with launch of MagnetOs Granules and MagnetOs Putty in New Zealand via an exclusive Mehr

Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA

4. Januar 2024 Firma Kuros BiosciencesForschung und Entwicklungautograft, bone, ecm, Gold, graft, implant, kuros, magnetos, market, maxa, patients, posterolateral, putty, statements, with

. New level 1 data from the MAXA Clinical Trial comparing standalone MagnetOs to the gold standard autograft in the challenging posterior spinal fusion approach, demonstrates a fusion rate of 78% versus 45% after one year In the difficult-to-treat patient Mehr

Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA

27. Dezember 2023 Firma Kuros BiosciencesMedizintechnikbone, ddd, ecm, fibrin, Gold, graft, kuros, magnetos, market, maxa, patients, posterolateral, pth, statements, with

In the MAXA trial, standalone MagnetOs outperformed the gold standard autograft by 73% in posterior spinal fusion in a difficult-to-treat real life patient population (20% smokers). In the STRUCTURE trial, MagnetOs mixed with autograft showed posterolateral fusion rates comparable Mehr

Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages

28. November 202329. November 2023 Firma Kuros BiosciencesFirmeninternbiomed, bone, ecm, extender, fibrin, flex, graft, kuros, magnetos, market, patients, posterolateral, pth, statements, with

MagnetOs is the first open fibrillar collagen matrix bone graft substitute to receive clearance to market for interbody use MagnetOs can now be used on-label in any interbody cage cleared for use with a bone void filler The exceptional Mehr

Kuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the Executive Management

12. Oktober 202316. Oktober 2023 Firma Kuros BiosciencesFinanzen / Bilanzenbone, chf, ebitda, ecm, fibrin, griffin, kuros, magnetos, market, patients, posterolateral, pth, revenue, statements, with

Direct MagnetOs sales grew to CHF 20.4 million in the first nine months of 2023, climbing from CHF 8.1 million in the same period in 2022. Total medical device sales accelerated from CHF 9.0 million to CHF 21.3 million Mehr

Kuros Biosciences Reports Results for First Half 2023

9. August 2023 Firma Kuros BiosciencesFinanzen / Bilanzenbone, chf, ebitda, ecm, fibrin, graft, kuros, magnetos, market, patients, posterolateral, pth, revenue, statements, with

. Financial Highlights Direct MagnetOs sales increased by 148% from CHF 4.9 million to CHF 12.2 million, total revenue from medical devices rose from CHF 5.7 million to CHF 12.9 million Medical Devices segment achieved a positive EBITDA of CHF Mehr

Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial

13. Juli 202313. Juli 2023 Firma Kuros BiosciencesForschung und Entwicklungbone, clinical, ddd, fibrin, fuse, graft, kuros, market, patients, posterolateral, pth, spinal, statements, tlif, with

First investigational trial of drug-biologic bone graft for spinal fusion 50 patients have been enrolled in the Phase 2 trial Potential to address $2.2B market opportunity Schlieren (Zurich), Switzerland, July 13, 2023 – Kuros Biosciences (“Kuros” or the “Company”), a Mehr

Annual General Meeting of Kuros Biosciences approves all resolutions

8. Mai 20238. Mai 2023 Firma Kuros BiosciencesFirmeninternbonds, bone, financial, forward, graft, its, kuros, looking, report, results, risks, shareholders, shares, statements, van

Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today. The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and the Consolidated Financial Statements for the year 2022 and took Mehr

Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 2023

27. April 202329. April 2023 Firma Kuros BiosciencesFinanzen / Bilanzenbone, chf, ebitda, ecm, fibrin, graft, implants, kuros, magnetos, market, patients, posterolateral, pth, statements, with

Direct MagnetOs sales climbed from CHF 2.0 million in Q1 2022 to CHF 5.4 million in Q1 2023. Total medical device sales accelerate from 2.6 million to CHF 5.6 million Key data on efficacy of MagnetOs bone graft published in Mehr

Autor: Firma Kuros Biosciences